Health technology assessment (HTA) processes vary across jurisdictions. Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands), others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria). In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions. However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt? This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated. The speakers will present different perspectives on evaluating the value of HTA processes and a discussant will provide an economist’s view.